17-AAG
Quick Overview for 17-AAG (ABIN1027730)
Application
Chemical Name
-
-
Purpose
- Hsp90 inhibitor
-
Characteristics
- Hsp90 inhibitor.
-
Purity
- >99 % (HPLC), NMR (Conforms)
-
Formula
- C31H43N3O8
-
Solubility
- Soluble in DMSO (>50 mg/ml) or ethanol (5 mg/ml)
-
-
-
-
Comment
-
Source: Synthetic.
Appearance: Red to dark red powder -
Restrictions
- For Research Use only
-
-
-
Format
- Solid
-
Precaution of Use
- Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection
-
Handling Advice
- Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection
-
Storage
- -20 °C
-
-
-
Background
- Glendanamycin (GA), a benzoquinone ansamycin antibiotic, interferes with the action of Hsp90 leading to degradation of Hsp90 client proteins. GA itself however has undesirable properties such as poor aqueous solubility and liver toxicity, therefore, numerous analogs have been synthesized, such as 17-AAG. 17-AAG is an HSP-90 inhibitor that displays a 100-fold higher affinity for HSP-90 derived from tumor cells compared to HSP-90 from normal cells. 17-AAG inhibits Akt activation and expression in tumors and synergizes with a number of antitumor agents such as taxol, cisplatin and UCN-01 (400 nM 17-AAG, U937 cells).
-
Molecular Weight
- 585.7
-
CAS-No
- 75747-14-7
-
-